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The objective of the study was to compare cold dry air (CDA) and histamine in differentiating pa-
tients with nonallergic noninfectious perennial rhinitis (NANIPER) from control subjects. Nasal reac-
tivity (nasal patency, mucus production, and sneezing) in 16 symptomatic nonsmoking patients with
NANIPER and seven nonsmoking control subjects was measured with standardized CDA and hista-
mine provocation series in a randomized crossover study. Intranasal CDA resulted in increased mucus
production and nasal blockage in a dose-dependent manner in patients with NANIPER but not in
control subjects. Sneezing did not occur. The reproducibility of CDA for patency and mucus produc-
tion was good. Sensitivity for CDA was 87% compared with 100% for histamine. However, specificity
was 71% for CDA and 0% for histamine. It is concluded that the new standardized intranasal CDA
provocation method uses a recognizable natural nonspecific stimulus and seems to be more suitable
than histamine for characterizing and assessing the presence and degree of nasal reactivity in NA-
NIPER. 
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Nonallergic noninfectious perennial rhinitis (NANIPER)
(also referred to as vasomotor rhinitis) was first described by
Wihl and colleagues (1). It is a chronic ongoing type of rhinitis
characterized by nasal hyperreactivity that results in nasal
blockage, mucus production, and sneezing (2, 3). The diagno-
sis is established by exclusion. When patients with noninfec-
tious rhinitis respond negatively to a skin prick test and when
symptoms persist throughout the year and no anatomic or
medical disorders of the nose are present, the diagnosis points
to NANIPER. No single diagnostic test, symptom, or clinical
feature exists to demonstrate the presence of this disorder.
Nor have distinct changes been found in cellular patterns in
the epithelium and lamina propria of the nasal mucosa (4).
Nasal hyperreactivity is an increased sensitivity of the nasal
mucosa to nonspecific stimuli and was first described by van
Lier (5). Cold dry air (CDA) provocation has been proven by
the Baltimore group to be an effective tool in quantifying the
secretory response of hyperreactivity in persons susceptible to
CDA (6, 7). In this population, significant changes were found
in cell mediators and neurogenic reflex mechanisms. It was,
however, not clear from which type of rhinitis these subjects
suffered or what happened to other nasal parameters such as
nasal patency or sneezing, important parameters when study-
ing blockers, runners, and sneezers. Pulmonary CDA provo-
cation of patients with asthma results in bronchial obstruction,
and it is found to be a suitable method for assessing bronchial
hyperreactivity (8).
Histamine and methacholine are the most widely used
provocation methods for measuring the degree of nasal hyper-
reactivity today. These tests have not been validated in pa-
tients with NANIPER. The objective of the study was to vali-
date and standardize a new intranasal CDA challenge method
and compare it with that of histamine. Nasal patency, mucus
production, and sneezing were studied after CDA and hista-
mine challenge in patients with NANIPER and in control sub-
jects. The dose dependency, sensitivity, specificity, and repro-
ducibility of both challenge methods were compared.
 
METHODS
 
Patients and Control Subjects
 
Thirty-eight patients and seven control subjects were selected on the
basis of inclusion and exclusion criteria (Table 1). These patients had
experienced nasal complaints such as nasal obstruction, sneezing, and/
or rhinorrhea for more than 1 yr. These symptoms could not be attrib-
uted to an atopic rhinitis, nasal or paranasal sinus infection, anatomic
disorders affecting nasal function, pregnancy or lactation, and/or sys-
temic disorders. Symptoms 2 wk prior to entry varied from moderate
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TABLE 2
STUDY DESIGN FOR NANIPER PATIENT GROUP A:
TIMETABLE FOR CROSSOVER PROVOCATION SERIES*
 
Run-in CDA or Histamine Histamine or CDA
Visits:
Days:
*Underlines 
 
5
 
 complete provocation series; boldface 
 
5
 
 provocation at predefined arbitrary threshold: average of the three previous
threshold doses resulting in 0.5 g mucus production and 30% patency reduction.
 
to severe (daily average of 2, on a scale of 0 to 4). Local and systemic
corticosteroids or antihistamine treatment had been stopped 4 wk
prior to the study, and xylometazoline had been stopped 6 hr prior to
each visit. There was no history of xylometazoline abuse.
A subgroup of 16 (five male, 11 female) of the 38 patients and all
seven control subjects (three male, four female) met additional re-
quirements: they were nonsmokers and avoided physical or chemical
irritants during the study (Group A). These additional restrictions
were not imposed on a second group of 16 patients (Group B), ran-
domly selected from the 22 remaining patients. The study was ap-
proved by the local medical ethical committee.
 
Study Design
 
The study had a randomized crossover controlled design. Patient
Group A and the seven control subjects visited the hospital on 16 oc-
casions. Participants were randomly assigned to start either with a
CDA challenge period of 4 wk followed by a 4-wk histamine chal-
lenge period or vice versa. These periods consisted of three complete
provocation series at weekly intervals. Subsequently, five daily repeat
challenges followed in order to test for possible increased responsive-
ness after repeat challenges (
 
see
 
 Table 2).
Patient Group B visited the hospital twice. After the run-in period,
patients were subjected to one CDA challenge in order to assess
whether patency, mucus production, and/or sneezing data of random
NANIPER sufferers responded to a function derived from the se-
lected patient Group A. The aim of this part of the study was to assess
external reproducibility.
 
Cold Dry Air
 
Subjects were allowed to acclimatize to room temperature (20
 
8
 
 C) for
15 min. Patients then blew their noses gently to remove remaining se-
cretions. The nose was then prerinsed with N saline. A respiratory
heat exchanger (Jaeger GmbH, Würzburg, Germany) was modified
slightly: Before cooling, the air was dried by passing it through a col-
umn with silicon granules. The temperature of the air leaving the sys-
tem was filtered and entered the nose at 
 
2
 
10
 
8
 
 C with a relative humid-
ity of 
 
, 
 
10%. A purpose-designed nose cap (Respricare, The Hague,
The Netherlands) ensured a tight fit. The dosage was increased in
steps by analogy with the histamine series as follows: 12.5, 25, 50, 100,
200, and 400 L. This involved CDA provocation steps of 1, 1, 2, 4, 8,
and 16 min with a flow of 12.5 for the first step and 25 L/min for the
following steps. Instructions were given to inhale through the nose
and exhale through the mouth during the challenge and to maintain
normal breathing frequency as at rest. The provocation was stopped
in case of hyperventilation. Anterior rhinomanometry (Rhinoscreen;
Jaeger) was repeated until no further decrease in patency was mea-
sured. Secretions were measured by weighing the amount of mucus
produced per provocation step in preweighed paper tissues on a preci-
sion scale (Mettler, Würzburg, Germany) with an accuracy of 0.01 g.
Sneezes were counted. Maximal effects per dose step were used for
calculations. Repeat measurements were performed every time the
dose was increased. Patency reduction and mucus production were
determined and sneezes were counted in the following 5 min (
 
see be-
low
 
). At the 400 L CDA step, patients were allowed to blow their
nose after 8 min in order to correct for drying of nasal secretions dur-
ing the 16-min provocation with CDA.
 
TABLE 1
CRITERIA FOR THE SELECTION OF PATIENTS WITH NONALLERGIC NONINFECTIOUS
PERENNIAL RHINITIS (NANIPER) AND CONTROL SUBJECTS
 
Inclusion criteria for patients with NANIPER and control subjects
16 to 65 yr of age
Negative skin prick test and negative RAST score
Symptoms for more than 1 yr (NANIPER only)
A cumulative score of 14 or more (Scale, 0 to 4) for overall nasal symptoms for at least 7 d during a period of 14 d 
(NANIPER only)
Exclusion criteria for patients with NANIPER and control subjects
The use of systemic or inhaled corticosteroids during the previous month
The use of inhaled cromoglycates, astemizol, or nedocromil sodium during the previous month
Inability of the patient to stop taking medication affecting nasal function (e.g., xylometazoline)
A serious and/or unstable disease and pregnancy or lactation
Nasal surgery during the previous 3 mo
Significant anatomic abnormalities affecting nasal function
Nasal polyps or a history of nasal polyps
Nasal or paranasal sinus infection or abnormal sinus radiograph
Abnormal laboratory results for:
 
Blood
 
: Na, K, Ca, total protein, albumin, urea, creatinine, bilirubin, alkaline phosphatase, aspartate aminotransferase,
analine aminotransferase, gamma glutamyl transpeptidase, hemoglobin, red blood cell count, plasma cell volume,
mean corpuscular volume, platelets, total white blood cell count, lymphocytes and monocytes, neutrophils,
eosinophils, and basophils.
 
Urine
 
: blood, protein, and glucose
Abnormal findings upon physical examination
Smoking (Group A)
Daily contact with physical or chemical irritants (Group A)
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Histamine
 
Acclimatization and prerinsing with N saline were the same as with
the CDA challenges. Histamine was used in the concentrations 0.125,
0.25, 0.5, 1, 2, and 4 mg/ml (9–11). Measurements started 1 min after
provocation and continued for 4 min, allowing adequate contact be-
tween histamine and the nasal epithelium.
 
Statistical Analysis
 
Thresholds of outcome parameters were calculated as the intersection
of the dose-response curve with the effect cutoff point. Reproducibil-
ity and dose dependency were assessed for the outcome parameters
“nasal patency” and “mucus production” separately by calculating re-
liability indices (RIs) (12) at several thresholds. The RI was defined as
the ratio of intersubject variance to total variance. Sensitivity and
specificity were determined at the “mean 100 dose” and the “mean
400 dose” (
 
see
 
 R
 
EPRODUCIBILITY
 
 and Table 3) and compared for CDA
and histamine using Fisher’s exact test.
Specificity was also calculated for maximal values and regression lines
of the outcome parameters. Regression line analysis was achieved by
pooling three consecutive provocation series and subsequent ln trans-
formation per patient using Biomedical Package Software (BMDP-5V;
BMDP Statistical Software, Inc., Los Angeles, CA). They represented
the function: ln(y/y
 
0
 
) 
 
5
 
 
 
2
 
ax. All regression lines started at the predefined
value of 100%; a, the slope coefficient of this regression line, represented
a decline or increase per doubling of the dose step. Differences between
patients with NANIPER and control subjects and between provocation
types were analyzed using the Mann-Whitney U test. Confidence analy-
sis was performed using SPSS PC software (SPSS Inc., Chicago, IL).
A random coefficient model with an intersubject grouping factor
in BMDP 5V software was used for (
 
1
 
) optimal curve estimation for
outcome parameters, (
 
2
 
) determination of a possible change in nasal
responsiveness after repeat provocations, and (
 
3
 
) calculations of cor-
relation coefficients between clinical features and outcome parame-
ters. The Mann-Whitney U test was used to compare carryover and
treatment effects. Intrapatient and control totals for the two provoca-
tion periods were used to test the carryover effect. The differences be-
tween intrapatient and control totals for two provocation periods
were used to test the treatment effect. We assumed that there was no
significant carryover or treatment effect if the means of these totals
did not significantly differ between the two provocation series. Medi-
ans of daily record chart data were analyzed with the Mann-Whitney
U test in three ways: (
 
1
 
) symptom score on the same day, (
 
2
 
) on the
previous day, and (
 
3
 
) as an average for the preceding week. Visual
Analogue Scales for (
 
1
 
) patency reduction, (
 
2
 
) mucus production, and
(
 
3
 
) sneezing were analyzed separately and as a total using the Mann-
Whitney U test.
 
TABLE 3
OVERVIEW OF CDA THRESHOLD DEFINITIONS
 
CDA dose
The dose resulting in 40% reduction of nasal patency and/or 0.5 g mucus
production (cutoff lines) in one CDA /histamine provocation series
400 dose
The dose 
 
<
 
 400 L CDA or 
 
<
 
 4 mg/ml histamine resulting in 40% reduction
of nasal patency and/or 0.5 g mucus production (cutoff lines) in one
CDA/histamine provocation series 
100 dose
The dose 
 
,
 
 100 L CDA or 1 mg/ml histamine resulting in 40% reduction of
nasal patency and/or 0.5 g mucus production (cutoff lines) in a CDA/ 
histamine provocation series
Mean 400 dose
The average of three repeat doses of which at least one resulted in a 
 
.
 
 400 
dose after three repeat histamine or CDA challenge series performed 
weekly. A positive response demonstrates the degree of nasal CDA reactivity 
in patients with NANIPER. It is reproducible and sensitive but less specific
Mean 100 dose
The average of three repeat doses of which at least one resulted in a 100 dose 
after three repeat histamine or CDA challenge series performed weekly. A
positive response demonstrates the presence of nasal CDA reactivity in 
patients with NANIPER. It is reproducible and less sensitive than mean 400
dose, but more specific
Figure 1. Optimal curve fits for observed patency results in percentages demonstrating intranasal CDA specificity and the lack of specificity
after intranasal histamine challenge: Curves (a) and (b) versus (c), statistically significant different slope coefficients; curves (d) and (e) not
statistically significant. External reproducibility of intranasal CDA challenge is shown: Curves (a) and (b), no statistically significant differ-
ence.
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RESULTS
 
Dose Dependency
 
CDA challenges were tolerated well throughout the study.
CDA provocation did not lead to sneezing of any importance.
Histamine challenge provoked sneezing, but not in a repro-
ducible or dose-dependent manner (data not shown). Nasal
patency and mucus production were dose-dependent outcome
parameters. To demonstrate and illustrate specificity, maxi-
mal effects and regression lines were also assessed (
 
see
 
 Figures
1 and 2).
 
Threshold Doses
 
Reproducibility and positivity for nasal CDA challenge.
 
 Cutoff
lines of 10, 20, 30, 40, and 50% patency reduction or 0.2, 0.3,
0.4, 0.5, 0.75, or 1.0 g mucus production were assessed. In or-
der to achieve an accurate calculation of reproducibility, the
first intersection of the dose-response line with the cutoff line
was calculated and used to determine the reproducibility of
the threshold dose. The test-retest reproducibility of one sin-
gle CDA provocation was inadequate.
In order to increase reproducibility for intranasal CDA
provocation, a series of three provocation series was per-
formed. Threshold doses were calculated for three repeated
provocations at intervals of 1 wk within a 2-wk period (mean
400 dose and mean 100 dose; 
 
see
 
 Table 3). The mean 400 dose
represented the mean of three threshold doses given at inter-
vals of 1 wk, which resulted in 40% nasal patency reduction
and/or 0.5 g mucus production after one challenge series. This
dose was used to evaluate intrapatient and interpatient differ-
ences. The mean 100 dose is similar to the mean 400 dose, with
the added restriction that this dose is reached at or before 100
L CDA or 1 mg/ml histamine in one of the three CDA or his-
tamine challenge series. Reproducibility was calculated by de-
termining the reliability index (RI) (12). Mean 400 dose and
mean 100 dose thresholds for CDA provocations in patients
with NANIPER resulted in a satisfactory RI of 76% for nasal
patency and a RI of 86% for mucus production. The RIs of
histamine challenge in patients with NANIPER for these
thresholds were 65 and 92%, respectively. For control sub-
jects, these RIs for patency and mucus production thresholds
were, respectively, 32 and 65% after CDA and 69 and 77% af-
ter histamine challenge. Thresholds at the other cutoff points
mentioned above resulted in lower RIs for CDA reactivity. As
a rule, histamine reactivity also resulted in lower RIs (results
not shown). When patients reached the mean 100 dose they
were considered to be CDA reactive. For statistical reasons,
patients who did not reach the 400 dose were considered to
have a threshold of 800 L CDA or 8 mg/ml histamine. When
reaching the 400 dose or the 100 dose after N saline, 6.25 L
CDA (or 0.0625 mg/ml histamine) was adopted as the basis for
calculations.
Figure 2. 95% confidence intervals pooled over all dose steps demonstrating for mucus production and nasal patency a dose-response
relationship. Less overlap between NANIPER Group A and the Control Group results for CDA- versus histamine-provoked mucus produc-
tion and patency decrease is clearly visible.
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Sensitivity, specificity, and degree of nasal CDA challenge.
 
The first dose step resulting in the 400 dose was considered to
be a positive reaction to intranasal CDA (Table 4). Sensitivity
was calculated as the number of patients with NANIPER re-
sponding positively to intranasal CDA divided by the total of
patients with NANIPER 
 
3
 
 100%. Specificity was calculated
as the number of control subjects with one or more positive
reactions (false positives) 
 
3
 
 100%. The mean 400 dose re-
sulted in a comparable sensitivity for CDA and histamine, 100
and 94%, respectively, whereas specificity was better for CDA
at 42% as opposed to 0%. This difference in specificity was
even more evident for the mean 100 dose (Table 5). The spec-
ificity of CDA compared with that of histamine was 71% as
opposed to 0%. Sensitivity for the mean 100 dose was a little
less when compared with the mean 400 dose at 87% as op-
posed to 94% (Table 5). For other histamine thresholds (for
patency and mucus production separately, or for a combina-
tion of patency and mucus production) a combination of less
sensitivity and specificity was found (results not shown).
The intrapatient standard deviations (SDs) for the doubled-
dose provocation steps were determined in order to assess the
degree of nasal reactivity to the mean 400 dose. Data for 15 of
the 16 patients were available. For nasal patency, respectively,
mucus production after CDA SDs were 1.1 and 0.9. For hista-
mine provocation these SDs were 0.8 versus 1.3. The same
SDs were found for the mean 100 dose.
In short, the presence of CDA reactivity in NANIPER was
best described by the mean 100 dose. This was a dose-depen-
dent, reproducible, sensitive, and specific threshold dose. Speci-
ficity was in favor of CDA rather than of histamine (p 
 
,
 
 0.05).
Sensitivity was the same for both provocation methods (p 
 
5
 
0.35). The degree of nasal CDA reactivity in NANIPER was
best described by the mean 400 dose. This dose was reproduc-
ible and sensitive but less specific than the mean 100 dose.
 
Maximal Effects Over all Dose Steps and
Regression Lines
 
The CDA challenge was superior to histamine in discriminat-
ing between patients with NANIPER and control subjects for
data of maximal effects on patency (CDA: p 
 
5
 
 0.003; hista-
mine: p 
 
5
 
 0.052) and for the same data of mucus production
(CDA: p 
 
5
 
 0.001; histamine: p 
 
5
 
 0.023) (
 
see
 
 Table 6).
A significant difference was found between the patency
slope coefficients of Group A and those of Group B patients
with NANIPER compared with control subjects (NANIPER
Group A versus control subjects: p 
 
5
 
 0.04). No statistical sig-
nificance was found between these curve slopes for histamine
(p 
 
5
 
 0.30). In the case of mucus production, the differences
between patients with NANIPER and control subjects were
even more apparent than for nasal patency (CDA: p 
 
5
 
 0.0021;
histamine: p 
 
5
 
 0.16) (
 
see
 
 Table 6).
In short, CDA provocation—expressed as maximal effects
and regression lines—resulted in better discrimination be-
tween patients with NANIPER and healthy control subjects
than did histamine provocation in terms of both nasal patency
and nasal mucus production. This is shown by the confidence
intervals for nontransformed data (Figure 2).
 
Variability.
 
 Variability after histamine provocation was
greater in patients with NANIPER than after CDA challenge
(
 
see
 
 Figure 3). In control subjects, however, histamine chal-
lenge resulted in lower variability than did CDA challenge.
 
External reproducibility.
 
 A second group of 16 patients
with NANIPER (Group B) was subjected to one CDA provo-
cation session in order to assess whether the patency and mu-
cus production data for other patients with NANIPER (those
who did not meet additional restrictions) corresponded to
those of Group A (external reproducibility). After plotting
the mucus production and patency data of patients from
Group A, a best-fit function was found to describe the patency
data only: ln(y/y
 
0
 
 
 
5
 
 
 
2b
 
x or y 
 
5
 
 y
 
0
 
 e
 
2b
 
x
 
, where y 
 
5
 
 nasal pa-
tency (ml/s); y
 
0
 
 
 
5
 
 preprovocation patency value; x 
 
5
 
 dose step
(preprovocation x 
 
5
 
 0; 400 L CDA or 4 mg/ml histamine x 
 
5
 
6); 
 
b
 
 
 
5
 
 slope coefficient.
Patency data after CDA provocation resulted in mean
slope coefficients 
 
b
 
 for NANIPER Groups A and B of 0.110
and 0.077, respectively. The difference between the groups
(0.033) was not statistically significant (p 
 
5
 
 0.14; 95% confi-
dence interval: 0.022 to 0.045), thus demonstrating external re-
producibility. For control subjects, 
 
b
 
 
 
5
 
 0.026. It was not possible
to find an adequate function to describe mucus production.
 
Correlation between clinical parameters and nasal reactivity.
 
(
 
1
 
) Prerinsing the nose with N saline, (
 
2
 
) patient’s perception
 
TABLE 4
DESCRIPTION OF NANIPER GROUPS A AND B AND CONTROL GROUP UNDER STUDY*
 
Subjects Age (
 
yr
 
)
Baseline
Patency
 
†
 
CDA 1–3
Baseline
Patency
 
†
 
Histamine 1–3
CDA Dose in Doubling Dose Steps
 
‡
 
Total IgE
(
 
E/ml
 
)CDA1 CDA1 CDA3 HIST1 HIST2 HIST3
NANIPER Group A,
n 
 
5
 
 16 44 
 
6 
 
10.9 527.6 
 
6 
 
163.5 518.2 
 
6 
 
185.2 4.25 
 
6 
 
1.78 3.93 
 
6 
 
2.46 3.88 
 
6 
 
2.29 1.59 
 
6 
 
1.28 2.65 
 
6 
 
1.85 1.90 
 
6 
 
1.71 48 
 
6 
 
24.6
NANIPER Group B,
n 
 
5
 
 16 37 
 
6 
 
12 856.7 
 
6 
 
139.5 ND 4.56 
 
6 
 
1.63 ND ND ND ND ND 160.0 
 
6 
 
45.0
Control group,
n 
 
5
 
 7 30 
 
6 
 
8.2 775.1 
 
6 
 
205.5 792.8 
 
6 
 
176.5 5.86 
 
6 
 
2.26 6.57 
 
6 
 
0.78 5.72 
 
6 
 
2.36 2.85 
 
6 
 
1.67 4.43 
 
6 
 
1.13 3.0 
 
6 
 
2.0 10 
 
6 
 
23.0
* Values are mean 
 
6
 
 SD. Baseline patency and threshold doses are normally distributed within population groups in this study.
 
†
 
 Flow in ml/s at 150 Pa.
 
‡
 
 1 
 
5
 
 0.12 mg/ml histamine or 12.5 L CDA; 6 
 
5
 
 4 mg/ml histamine or 400 L CDA.
 
TABLE 5
SENSITIVITY AND SPECIFICITY RESULTS FOR CDA AND
HISTAMINE CHALLENGES CALCULATED AT MEAN
100 DOSE AND MEAN 400 DOSE*
 
Cold Dry Air Histamine
Sensitivity Specificity Sensitivity Specificity
Mean 100 dose
14/16 (87%) 5/7 (71%) 16/16 (100%) 0/7 (0%)
Mean 400 dose
15/16 (94%) 3/7 (42%) 16/16 (100%) 0/7 (0%)
* The sensitivity of the two challenge types is more or less equal. The specificity of
histamine challenge, on the other hand, is far less than that of CDA provocation. Only
combined patency and/or mucus production data were assessed. For patency and mu-
cus production data taken separately, similar percentages were found (data not shown).
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of the nasal symptoms as expressed by a daily record chart or
visual analogue scale, and (3) the color of the nasal mucosa
were not statistically significant correlated with the mean 400
dose or the mean 100 dose.
Tachyphylaxis: increased responsiveness, carryover, or
treatment effect? The responses to 100 dose and 400 dose (see
Table 3) of CDA/histamine provocation series on Day 5 were
compared with the responses to the mean 100 dose and mean
400 dose administered during the previous 2 wk. No statisti-
cally significant change was noted in the response to the 100
dose and the 400 dose during the CDA provocation period.
Histamine provocation, however, gave an increased respon-
siveness effect for the 100 dose and the 400 dose (p 5 0.025).
A carryover effect was not found (p 5 0.13). Nor was any
treatment effect of histamine after CDA or vice versa found
(p 5 0.27).
DISCUSSION
This study has shown that, unlike histamine, intranasal CDA
provocation is a reliable method for measuring nasal reactivity
symptoms in patients with NANIPER in a dose-dependent
and, for patients with NANIPER, recognizable way. CDA
challenge is a natural stimulus, although exposure conditions
are artificial. CDA is thought to provoke neurogenic reflex
mechanisms in the nasal mucosa (2, 3). In this study, the as-
sessment of intranasal CDA reactivity is based on nasal pa-
tency and mucus production as the two main outcome param-
eters, making the method very suitable for studying nasal
hyperreactivity in patients with NANIPER (blockers and run-
ners). Although time-consuming, it has been found to be a
well tolerated, safe, and easy to dose provocation method. Its
relation to histamine and the separate assessment of patency
TABLE 6
RESULTS FOR THE ALTERNATIVE OUTCOME PARAMETERS:
MAXIMUM EFFECT AND REGRESSION LINE ANALYSIS*
Maximum Effect Regression Line
95%
Confidence
95%
ConfidencePatency
Mucus
Production Patency
Mucus
Production
CDA
Patient Group A 0.51 0.72 28.13 0.12 211.0 to 25.2 0.066 to 0.16
Control group 0.26 0.27 22.70 0.04 25.7 to 3.4 0.006 to 0.071
p Values p 5 0.003 p 5 0.001 p 5 0.04 p 5 0.0021
Histamine
Patient Group A 0.67 1.53 29.17 0.18 212.4 to 25.9 0.09 to 0.60
Control group 0.42 0.94 26.30 0.19 28.6 to 24.2 0.088 to 0.28
p Values p 5 0.052 p 5 0.023 p 5 0.30 p 5 0.16
* The specificity of CDA provocation is shown by the significant differences between patients with NANIPER and control subjects. Hista-
mine challenge failed to make this distinction. Note that a 0.071 g increase of mucus production per dose step after CDA challenge indi-
cates NANIPER.
Figure 3. Box plot diagrams demonstrating a large variability of patency results of patients with NANIPER after histamine provocation
compared with CDA provocation. In control subjects no significant differences were found between CDA provocation doses and prechal-
lenge values, whereas histamine showed a significant decrease. *p , 0.05, **p , 0.01 (paired t test).
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reduction, mucus production, and sneezing have, to our knowl-
edge, not been studied previously.
Patients with NANIPER are an interesting group to study
because no single test had been developed until now for moni-
toring changes in this condition. A common and characteristic
feature of patients with NANIPER is nasal hyperreactivity.
Until now, the most common diagnostic test for measuring na-
sal hyperreactivity was intranasal histamine provocation. His-
tamine provocation, however, fails to differentiate between
patients with NANIPER and control subjects. CDA is able to
make this distinction. We therefore find that CDA is superior
to histamine challenge for diagnosing NANIPER. CDA chal-
lenge could be an alternative to histamine in characterizing
nonspecific nasal hyperreactivity in other subgroups of rhini-
tis, examples being allergic (9), nonallergic (10, 15), and infec-
tious (14) rhinitis.
As cigarette smoke (16) and ozone (17) have been proven
to induce airway hyperreactivity, we tried to eliminate these
factors in the first group of patients with NANIPER (Group
A), as mentioned in Table 1. We were able to demonstrate
corresponding results for nasal patency in a second NA-
NIPER group without these additional restrictions (Group B),
indicating that in this study these environmental factors were
not of major importance.
A reproducible measure for intranasal CDA provocation
was difficult to establish. Sneezing, one of the three outcome
parameters, was not useful. Several criteria for mucus produc-
tion and patency such as maximal effects, regression line coef-
ficients, and threshold doses at several cutoff points were as-
sessed. Single measurements did not result in a reproducible
measure. In order to achieve acceptable reproducibility and
sensitivity in both histamine and CDA challenges, requiring as
little time as possible, repeated measurements expressed as
mean 100 dose and mean 400 dose (see Table 3) were needed.
However, specificity was acceptable only in the case of CDA
challenge. It was not possible to achieve comparable specific-
ity for histamine challenge using other threshold doses.
In this study, three complete provocation series were per-
formed. This study has demonstrated that the 100 dose is in-
dicative of the presence of CDA reactivity. As soon as the 100
dose is reached, the subsequent dose steps in the series are un-
necessary. The degree of CDA reactivity will be indicated by
the mean 400 dose. It will be possible to note changes in CDA
reactivity, bearing in mind intrasubject variability.
Repeated daily CDA or histamine provocations for 5 d did
not lead to increased responsiveness for CDA, but it did so for
histamine. Some studies (18, 19) report unchanged nasal re-
sponsiveness to histamine after repeated histamine challenges,
but these studies are difficult to compare to ours. Gronburg
and colleagues (18) rechallenged nonrhinitic subjects after 1 h
and 1 d, whereas Ohm and Juto (19) rechallenged nonallergic
rhinitis subjects on three to seven occasions, sometimes at in-
tervals of several weeks. A possible explanation for our find-
ing that repeated histamine challenges lead to increased re-
sponsiveness could be that we used five consecutive daily
provocations and that these resulted in increased inflamma-
tion. Söderberg and colleagues (20) found that bronchial his-
tamine challenges lead to an increase in inflammatory cells in
bronchoalveolar fluid 24 h after the inhalation of histamine in
normal subjects.
Surprisingly, several clinical parameters such as symptom
scores and visual analogue scales correlated poorly with CDA
and histamine reactivity in patients with NANIPER. In pa-
tients with perennial allergic rhinitis, however, De Graaf and
colleagues (21) found significant correlations between nasal
responsiveness to histamine and symptom scores for the pre-
ceding 2 wk. Hallen and Juto (22) found reasonable correlations
between symptom scores for the preceding 2 wk and hista-
mine reactivity of nasal mucosa in nonallergic nasal-hyperre-
active patients. The reason for the conflict with our findings
could be that the thrice-weekly CDA/histamine provocations
interfered with the natural symptomatology of NANIPER.
Earlier biopsy studies in patients with NANIPER did not
support the hypothesis of cellular inflammation (4). This
emphasizes the need for further investigation of neurogenic
structures and mediators such as neuropeptides in hyperreac-
tive nasal mucosa. Further studies evaluating the effects of
CDA/histamine challenge on these parameters are in progress.
This new standardized intranasal CDA provocation method
uses a recognizable natural nonspecific stimulus and seems to
be more suitable than histamine for characterizing and assess-
ing the presence and degree of nasal reactivity in NANIPER.
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